Voyager Therapeutics (NASDAQ:VYGR) Given New $8.00 Price Target at Wedbush

Voyager Therapeutics (NASDAQ:VYGR) had its target price reduced by Wedbush from $10.00 to $8.00 in a research note issued to investors on Tuesday morning, Benzinga reports. They currently have a neutral rating on the stock. Wedbush also issued estimates for Voyager Therapeutics’ Q2 2024 earnings at ($0.46) EPS, Q3 2024 earnings at ($0.51) EPS, Q4 2024 earnings at ($0.52) EPS, FY2024 earnings at ($1.69) EPS, Q1 2025 earnings at ($0.61) EPS, Q2 2025 earnings at ($0.64) EPS, Q3 2025 earnings at ($0.53) EPS, Q4 2025 earnings at ($0.55) EPS, FY2025 earnings at ($2.32) EPS, FY2026 earnings at ($2.25) EPS, FY2027 earnings at ($1.95) EPS and FY2028 earnings at ($1.74) EPS.

Other research analysts also recently issued reports about the company. Guggenheim assumed coverage on Voyager Therapeutics in a research note on Tuesday, March 26th. They issued a buy rating and a $22.00 price target for the company. HC Wainwright initiated coverage on shares of Voyager Therapeutics in a report on Tuesday, March 19th. They set a buy rating and a $30.00 target price on the stock. StockNews.com cut shares of Voyager Therapeutics from a buy rating to a hold rating in a research note on Monday, May 13th. Finally, Citigroup assumed coverage on shares of Voyager Therapeutics in a research note on Thursday, March 7th. They set a buy rating and a $16.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, Voyager Therapeutics presently has a consensus rating of Moderate Buy and a consensus price target of $18.00.

Voyager Therapeutics Trading Down 2.3 %

Voyager Therapeutics stock opened at $8.43 on Tuesday. The company has a 50 day moving average of $8.75 and a 200-day moving average of $8.11. Voyager Therapeutics has a twelve month low of $6.06 and a twelve month high of $14.34.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings data on Wednesday, February 28th. The company reported $1.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $1.84. Voyager Therapeutics had a negative return on equity of 1.28% and a negative net margin of 2.56%. The business had revenue of $90.06 million during the quarter, compared to the consensus estimate of $4.95 million. As a group, analysts anticipate that Voyager Therapeutics will post -1.42 EPS for the current fiscal year.

Hedge Funds Weigh In On Voyager Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Kestra Advisory Services LLC bought a new stake in shares of Voyager Therapeutics during the third quarter worth $980,000. Ritholtz Wealth Management lifted its stake in shares of Voyager Therapeutics by 11.8% in the 4th quarter. Ritholtz Wealth Management now owns 19,759 shares of the company’s stock valued at $167,000 after acquiring an additional 2,089 shares during the last quarter. Alps Advisors Inc. acquired a new stake in shares of Voyager Therapeutics during the 3rd quarter valued at $294,000. China Universal Asset Management Co. Ltd. bought a new stake in Voyager Therapeutics during the 4th quarter worth $43,000. Finally, Aigen Investment Management LP acquired a new position in Voyager Therapeutics in the 3rd quarter worth about $109,000. Institutional investors own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.